Literature DB >> 35810680

Adaptive immune responses to Kaposi's sarcoma-associated herpesvirus.

Angela Nalwoga1, Denise Whitby2.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is a gammaherpesvirus that causes Kaposi's sarcoma (KS), primary effusion lymphoma, multicentric Castleman's disease and KSHV-induced cytokine syndrome. KSHV established lifelong infection and has evolved numerous ways in which to evade adaptive immune responses. Most KSHV infections are asymptomatic but when disease occurs it does so in the context of immune suppression especially HIV infection. It is important therefore to study immune responses to KSHV in order to understand KSHV-related disease pathogenesis.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35810680      PMCID: PMC9578218          DOI: 10.1016/j.coi.2022.102230

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.268


  47 in total

1.  Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus.

Authors:  C Brander; T Suscovich; Y Lee; P T Nguyen; P O'Connor; J Seebach; N G Jones; M van Gorder; B D Walker; D T Scadden
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

2.  KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma.

Authors:  S J Gao; L Kingsley; M Li; W Zheng; C Parravicini; J Ziegler; R Newton; C R Rinaldo; A Saah; J Phair; R Detels; Y Chang; P S Moore
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

Review 3.  HIV-associated Kaposi sarcoma and related diseases.

Authors:  Priscila H Gonçalves; Thomas S Uldrick; Robert Yarchoan
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

4.  The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women.

Authors:  D H Kedes; D Ganem; N Ameli; P Bacchetti; R Greenblatt
Journal:  JAMA       Date:  1997-02-12       Impact factor: 56.272

5.  Mother-to-child transmission of human herpesvirus-8 in South Africa.

Authors:  Martin Dedicoat; Robert Newton; Khaled R Alkharsah; Julie Sheldon; Ildiko Szabados; Bukekile Ndlovu; Taryn Page; Delphine Casabonne; Charles F Gilks; Sharon A Cassol; Denise Whitby; Thomas F Schulz
Journal:  J Infect Dis       Date:  2004-08-11       Impact factor: 5.226

6.  The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals.

Authors:  F Guedes; H F de Andrade; E R Fernandes; F F Tuon; R A Brasil; C Pagliari; M I S Duarte
Journal:  Br J Dermatol       Date:  2008-07-17       Impact factor: 9.302

Review 7.  Immune control of oncogenic γ-herpesviruses.

Authors:  Jae Jung; Christian Münz
Journal:  Curr Opin Virol       Date:  2015-09-13       Impact factor: 7.090

8.  Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda.

Authors:  Angela Nalwoga; Romin Roshan; Kyle Moore; Vickie Marshall; Wendell Miley; Nazzarena Labo; Marjorie Nakibuule; Stephen Cose; Rosemary Rochford; Robert Newton; Denise Whitby
Journal:  Nat Commun       Date:  2021-12-16       Impact factor: 14.919

9.  Malaria Is Associated With Kaposi Sarcoma-Associated Herpesvirus Seroconversion in a Cohort of Western Kenyan Children.

Authors:  Katherine R Sabourin; Ibrahim Daud; Sidney Ogolla; Nazzarena Labo; Wendell Miley; Molly Lamb; Robert Newton; Denise Whitby; Rosemary Rochford
Journal:  J Infect Dis       Date:  2021-07-15       Impact factor: 5.226

10.  Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study.

Authors:  Katie Wakeham; W Thomas Johnston; Angela Nalwoga; Emily L Webb; Billy N Mayanja; Wendell Miley; Alison M Elliott; Denise Whitby; Robert Newton
Journal:  Int J Cancer       Date:  2014-11-28       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.